(Q44133396)

English

The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients

scientific article published in January 2013

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

lymphoblastic leukemia

1 reference

based on heuristic

inferred from title

author name string

C Kellner

1

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

E A Zhukovsky

2

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

A Pötzke

3

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

M Brüggemann

4

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

A Schrauder

5

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

M Schrappe

6

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

M Kneba

7

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

R Repp

8

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

A Humpe

9

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

M Gramatzki

10

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

M Peipp

11

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

publication date

1 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

1595-1598

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Chemoimmunotherapy in acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.373

21 January 2018

A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.373

21 January 2018

A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.373

21 January 2018

Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.373

21 January 2018

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.373

21 January 2018

Antibodies, Fc receptors and cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.373

21 January 2018

In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.373

21 January 2018

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.373

21 January 2018

Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.373

21 January 2018

CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.373

21 January 2018

XmAb-5574 antibody demonstrates superior antibody-dependent cellular cytotoxicity as compared with CD52- and CD20-targeted antibodies in adult acute lymphoblastic leukemia cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.373

21 January 2018

Chimeric CD19 antibody mediates cytotoxic activity against leukemic blasts with effector cells from pediatric patients who received T-cell-depleted allografts

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.373

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.373

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2012.373

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44133396&oldid=2206454998"